StockData
Champions Oncology, Inc. logo

Champions Oncology, Inc. (CSBR) stock

CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.59−0.09 (-1.89%)

Close on Nov 17, 2026Market cap $63.91MP/E –Yield –

Champions Oncology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Champions Oncology's operating income for the twelve months ending Jul 31, 2026 was -$1.02M, down 137.9% year over year. For fiscal 2026 it was -$1.14M, down 125.0% from the year before. The highest annual figure on record is $4.55M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2026Apr 30, 2026-$1.14M-125.0%
FY2025Apr 30, 2025$4.55M–
FY2024Apr 30, 2024-$7.36M–
FY2023Apr 30, 2023-$5.26M-965.9%
FY2022Apr 30, 2022$607.00K+65.8%
FY2021Apr 30, 2021$366.00K–
FY2020Apr 30, 2020-$1.92M-811.5%
FY2019Apr 30, 2019$270.00K–
FY2018Apr 30, 2018-$1.35M–
FY2017Apr 30, 2017-$6.81M–
FY2016Apr 30, 2016-$10.32M–
FY2015Apr 30, 2015-$13.24M–
FY2014Apr 30, 2014-$6.26M–
FY2013Apr 30, 2013-$6.22M–
FY2012Apr 30, 2012-$9.07M–
FY2011Apr 30, 2011-$5.24M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026-$409.00K–
Q4 FY2026CQ1 2026Apr 30, 2026-$522.00K–
Q3 FY2026CQ4 2025Jan 31, 2026-$276.00K-106.1%
Q2 FY2026CQ3 2025Oct 31, 2025$185.00K-74.7%
Q1 FY2026CQ2 2025Jul 31, 2025-$527.00K-139.7%
Q4 FY2025CQ1 2025Apr 30, 2025-$2.01M–
Q3 FY2025CQ4 2024Jan 31, 2025$4.50M–
Q2 FY2025CQ3 2024Oct 31, 2024$732.00K–
Q1 FY2025CQ2 2024Jul 31, 2024$1.33M–
Q4 FY2024CQ1 2024Apr 30, 2024-$271.00K–
Q3 FY2024CQ4 2023Jan 31, 2024-$2.58M–
Q2 FY2024CQ3 2023Oct 31, 2023-$1.96M-28028.6%
Q1 FY2024CQ2 2023Jul 31, 2023-$2.55M–
Q4 FY2023CQ1 2023Apr 30, 2023-$2.52M–
Q3 FY2023CQ4 2022Jan 31, 2023-$2.46M-396.1%
Q2 FY2023CQ3 2022Oct 31, 2022$7.00K-97.3%
Q1 FY2023CQ2 2022Jul 31, 2022-$284.00K–
Q4 FY2022CQ1 2022Apr 30, 2022-$311.00K–
Q3 FY2022CQ4 2021Jan 31, 2022$830.00K-15.5%
Q2 FY2022CQ3 2021Oct 31, 2021$263.00K+3657.1%
Q1 FY2022CQ2 2021Jul 31, 2021-$175.00K-829.2%
Q4 FY2021CQ1 2021Apr 30, 2021-$648.00K–
Q3 FY2021CQ4 2020Jan 31, 2021$982.00K+126.8%
Q2 FY2021CQ3 2020Oct 31, 2020$7.00K-97.6%
Q1 FY2021CQ2 2020Jul 31, 2020$24.00K–
Q4 FY2020CQ1 2020Apr 30, 2020-$2.03M–
Q3 FY2020CQ4 2019Jan 31, 2020$433.00K–
Q2 FY2020CQ3 2019Oct 31, 2019$291.00K+5.8%
Q1 FY2020CQ2 2019Jul 31, 2019-$614.00K-227.7%
Q4 FY2019CQ1 2019Apr 30, 2019-$116.00K–
Q3 FY2019CQ4 2018Jan 31, 2019-$370.00K–
Q2 FY2019CQ3 2018Oct 31, 2018$275.00K–
Q1 FY2019CQ2 2018Jul 31, 2018$481.00K–
Q4 FY2018CQ1 2018Apr 30, 2018-$599.00K–
Q3 FY2018CQ4 2017Jan 31, 2018-$67.00K–
Q2 FY2018CQ3 2017Oct 31, 2017-$70.00K–
Q1 FY2018CQ2 2017Jul 31, 2017-$619.00K–
Q4 FY2017CQ1 2017Apr 30, 2017-$2.39M–
Q3 FY2017CQ4 2016Jan 31, 2017-$1.40M–
Q2 FY2017CQ3 2016Oct 31, 2016-$493.00K–

More Champions Oncology figures

See a number that looks wrong?